Intravenous tenecteplase administered 4.5 to 24 hours after symptom onset improved the likelihood of excellent functional outcome at 90 days in patients with acute ischemic #stroke due to non–large vessel occlusion and salvageable brain tissue, compared with standard medical treatment. In this randomized clinical trial, 43.6% of patients receiving #tenecteplase achieved a modified Rankin Scale score of 0 or 1 vs 34.2% with standard care, but use of tenecteplase was associated with a higher incid